CN Patent

CN113024517A — 一种制备厄达替尼的方法

Assigned to Wuhan Jiuzhou Yumin Medical Technology Co ltd · Expires 2021-06-25 · 5y expired

What this patent protects

本发明提供了一种制备厄达替尼的方法。本发明所述的方法，反应步数仅有4步，且卤代反应产物收率高。本发明所述的合成路线，不仅减少了反应步数，还提高了反应的总收率，有效降低了终产物成本，且有利于实现该产品的工业化生产。

USPTO Abstract

本发明提供了一种制备厄达替尼的方法。本发明所述的方法，反应步数仅有4步，且卤代反应产物收率高。本发明所述的合成路线，不仅减少了反应步数，还提高了反应的总收率，有效降低了终产物成本，且有利于实现该产品的工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN113024517A
Jurisdiction
CN
Classification
—
Expires
2021-06-25
Drug substance claim
No
Drug product claim
No
Assignee
Wuhan Jiuzhou Yumin Medical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.